Sapevo dell’esistenza di questo liquido respirabile (perfluorocarbon) da qualche anno e, convinto di una sua applicazione in ambito FC, ho trovato su internet delle informazioni promettenti. Ovviamente l’obiettivo è sempre unico, rendere reversibili le condizioni polmonari compromesse, il più possibile. In FC si potrebbe utilizzare questo liquido iniziando a riempire parzialmente i polmoni, per far distaccare e galleggiare il muco, che altrimenti non sarebbe espulso, fino a che la sua fuoriuscita non sarà più traumatica, anche riempiendo i polmoni, per effetto della pulizia delle lavande precedenti. Ma leggendo meglio, questo liquido respirabile, può essere usato anche per risolvere più rapidamente le infezioni polmonari. Ritengo quindi giustificata questa segnalazione ma sarebbe molto utile verificare se qualche laboratorio sta facendo sperimentazioni o se sarebbe interessato a farle o cosa ne pensa il Dott. Mastella e gli esperti che collaborano con la Fondazione.

Riporto il testo in inglese e consultabile a questo link ricco di referenze: http://en.wikipedia.org/wiki/Perflubron#Medical_treatment Medical treatment. “The most promising area for the use of liquid ventilation is in the field of pediatric medicine.[20][21][22] The first medical use of liquid breathing was treatment of premature babies[23][24][25] [26]and adults with acute respiratory distress syndrome (ARDS) in the 1990s. Liquid breathing was used in clinical trials after the development by Alliance Pharmaceuticals of the fluorochemical perfluorooctyl bromide, or perflubron for short. Current methods of positive-pressure ventilation can contribute to the development of lung disease in pre-term neonates, leading to diseases such as bronchopulmonary dysplasia. Liquid ventilation removes many of the high pressure gradients responsible for this damage. Furthermore, Perfluorocarbons have been demonstrated to reduce lung inflammation,[27][28][29] improve ventilation-perfusion mismatch and to provide a novel route for the pulmonary administration of drugs.[30][31][32] Clinical trials with premature infants, children and adults were conducted. Since the safety of the procedure and the effectiveness were apparent from an early stage, the US Food and Drug Administration (FDA) gave the product “fast track” status (meaning an accelerated review of the product, designed to get it to the public as quickly as is safely possible) due to its life-saving potential. Clinical trials showed that using perflubron with ordinary ventilators improved outcomes as much as using high frequency oscillating ventilation (HFOV). But because perflubron was not better than HFOV, the FDA did not approve perflubron, and Alliance is no longer pursuing the partial liquid ventilation application. Whether perflubron would improve outcomes when used with HFOV remains an open question. In 1996 Mike Darwin and Dr. Steven B. Harris proposed using cold liquid ventilation with perfluorocarbon to quickly lower the body temperature of victims of cardiac arrest and other brain trauma to allow the brain to better recover.[33] The technology came to be called gas/liquid ventilation (GLV), and was shown able to achieve a cooling rate of 0.5 degrees Celsius per minute in large animals.[34] It has not yet been tried in humans. Most recently, hypothermic brain protection has been associated with rapid brain cooling. In this regard, a new therapeutic approach is the use of intranasal perfluorochemical spray for preferential brain cooling[35]. The nasopharyngeal (NP) approach is unique for brain cooling due to anatomic proximity to the cerebral circulation and arteries. Based on preclinical studies in adult sheep, it was shown that independent of region, brain cooling was faster during NP-perfluorochemical versus conventional whole body cooling with cooling blankets. Preliminary phase I clinical trials are ongoing using this new therapeutic procedure.